Zevra Therapeutics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
Zevra Therapeutics, Inc. (ZVRA) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $5.00 per share for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2020-02-28
- Zevra Therapeutics, Inc. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2019 was $5.00.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|
| 2019-12-31 | $5.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |